Can Wellbutrin Cause Psychosis?
Yes, Wellbutrin (bupropion) can cause psychosis, though this is an uncommon adverse effect that is explicitly recognized in the FDA drug label. The FDA labeling specifically warns that depressed patients treated with bupropion have experienced neuropsychiatric signs and symptoms including delusions, hallucinations, psychosis, concentration disturbance, paranoia, and confusion 1.
Risk Profile and Clinical Context
The risk of bupropion-induced psychosis appears to be dose-dependent and influenced by specific patient factors:
Key Risk Factors:
- Higher doses (particularly above 300 mg/day) carry increased risk 2, 3, 4, 5
- Absence of concurrent antipsychotic medication - 93% of reported psychosis cases occurred without antipsychotic coverage 6
- Immediate-release formulations - 57% of psychosis cases were associated with IR formulations rather than sustained or extended-release 6
- Pre-existing psychotic symptoms or bipolar disorder - particularly those with psychotic features 1, 2, 4
- Substance use disorders, especially alcohol 4, 7
- History of head trauma or older age 3
Timeline and Presentation:
Psychotic symptoms typically emerge after an average of 10 days at 300 mg/day 5. The presentation commonly includes:
- Auditory, visual, or cenesthetic hallucinations (85% of cases)
- Persecutory or mystical delusions
- Restlessness and confusion
- Symptoms resembling amphetamine-induced acute psychosis 5
Evidence from Clinical Trials
The most reassuring data comes from patients on stable antipsychotic regimens. A systematic review found that 229 schizophrenic patients on stable antipsychotic medications were successfully treated with bupropion and experienced marked clinical improvement without developing psychosis 6. This suggests the risk is negligible when antipsychotics provide dopaminergic blockade.
However, the 2016 NCCN guidelines note that while uncommon, providers should monitor for development or worsening of serious neuropsychiatric issues including depression and suicidal ideation/behavior, and discontinue use if these signs occur 8. Importantly, a large multicenter RCT (EAGLES trial) found that neuropsychiatric adverse events with bupropion were not significantly increased relative to nicotine patches or placebo in patients with or without psychiatric disorders 8.
Management Algorithm
If psychosis develops:
- Immediately discontinue bupropion - this is the primary intervention 1, 3, 5
- Expect resolution within 7-10 days of discontinuation 3, 5
- Consider antipsychotics (such as risperidone) if symptoms are severe, though benzodiazepines may suffice for milder cases following the amphetamine-induced psychosis model 3, 5
- Do not rechallenge - symptoms recur upon reintroduction 7
Clinical Recommendations
For patients WITHOUT psychotic disorders:
- Use extended-release formulations preferentially
- Start at 150 mg/day and titrate cautiously
- Monitor closely in the first 2 weeks, especially after dose increases
- Avoid in patients with substance use disorders, particularly active alcohol use
For patients WITH schizophrenia or psychotic disorders:
- Bupropion can be used safely only if maintained on adequate antipsychotic coverage 6
- The combination appears protective against psychosis induction
- Monitor for pharmacokinetic interactions, though these are rare 6
- Be aware that EEG abnormalities occur frequently with this combination 6
For patients with bipolar disorder:
- Screen carefully for history of psychotic features before initiating 1, 2
- Exercise particular caution with doses above 150 mg/day in those with psychotic features 2
- Monitor closely after any dose escalation
Critical Caveat:
The FDA label explicitly states that some patients with psychosis had a diagnosis of bipolar disorder, and symptoms often abated upon dose reduction or withdrawal 1. This underscores the importance of proper psychiatric screening before initiation, as bupropion can precipitate manic or hypomanic episodes with psychotic features 1, 2.